| Results implicate RASAL2 as an EMT regulator and tumor suppressor in ovarian cancer, and down-regulation of RASAL2 promotes ovarian cancer progression. | ovarian, |
| Study shows that up to 62% of luminal B cancers have lost expression of at least one of the DAB2IP and RASAL2 genes. However, the tumors that have lost both genes frequently present as advanced disease and are more likely to recur. Importantly, the report provide evidence that DAB2IP and RASAL2 can individually function as tumor suppressors in breast cancer. | breast, |
| The RasGAP gene, RASAL2, is a tumor and metastasis suppressor | None |
| these results demonstrated that miRNA-136 was a key anti-invasive miRNA and further confirmed the oncogenic role of RASAL2 in triple-negative breast cancer. | breast, |
| Furthermore, overexpression of miR-203 exhibited a similar effect to RASAL2 knockdown in hepatocellular carcinoma (HCC) cells. These results indicated that RASAL2 serves a tumor oncogenic role in HCC and may be considered a potential target in HCC. | liver, |